Buy Piracetam solution 200 mg/ml 5 ml 10 pcs
  • Buy Piracetam solution 200 mg/ml 5 ml 10 pcs

Piracetam

Pharmstandard Ufavita
10000 Items
2019-06-23
Dosage form
Brand & Manufacturer
Package Size
$19.75
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people. Stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves communication between the cerebral hemispheres and synaptic conduction in the cortex, improves mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases the activity of phospholipase A, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates the exchange of neurotransmitters.

Piracetam increases the resistance of the brain tissue to toxic effects and hypoxia, enhances the synthesis of phospholipids and nuclear RNA, enhances glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through the microvessels and the conformational properties of the erythrocyte membrane, and increases regional blood flow in the ischemic brain regions. Piracetam enhances EEG beta and alpha activity and lowers delta activity. Reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effects has a neuroprotective effect.

Due to its antihypoxic effect, piracetam is effective in the complex treatment of myocardial infarction. Anxiolytic and sedative effects of piracetam are absent.

Almost completely and quickly piracetam absorbed after ingestion. Bioavailability is 100%. When ingestion of 2 g of the drug, the maximum plasma concentration is 40-60 μg / ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2–8 hours, the maximum concentration in the liquor is created. Piracetam penetrates all tissues and organs, and penetrates through the placental barrier. Almost not metabolized. Selectively accumulates in the cerebral cortex, mainly in the parietal, frontal and occipital lobes, basal ganglia and cerebellum. The plasma half-life of piracetam is 4–5 hours; from liquor is 6-8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. In patients with renal failure, the elimination half-life increases.

Indications

  • Chronic cerebrovascular insufficiency (hypertension, atherosclerosis, vascular parkinsonism), which is accompanied by a violation of attention, memory, speech, headache and dizziness;
  • ischemic stroke and its consequences;
  • psychoorganic disorders;
  • dementia (senile dementia, Alzheimer's disease, vascular dementia);
  • traumatic brain injury;
  • acute viral neuroinfection;
  • intoxication (recovery period, coma and subcomatal state);
  • diseases of the nervous system, which are accompanied by a decrease in the level of wakefulness, intellectual-mnestic functions, violation of behavior and emotional-volitional sphere;
  • dizziness;
  • vestibular nystagmus;
  • sluggish apathetic condition;
  • aphasia;
  • cortical myoclonia;
  • epilepsy (as an adjunct);
  • senile and atrophic processes;
  • depressive conditions that are resistant to treatment with antidepressants;
  • prevention or elimination of neurological, somatovegetative, mental complications of treatment with neuroleptics and other psychotropic drugs;
  • neurotic depression with a prevalence of senesto-hypochondriac and asthenic disorders, adynamia, and ideomotor retardation in the clinical picture;
  • psychoorganic syndrome in chronic alcoholism;
  • relief of pre - and delirious, withdrawal states in drug addiction and alcoholism;
  • acute intoxication with morphine, ethanol, amphetamine, barbiturates;
  • in children - cerebral palsy, the effects of perinatal damage to the central nervous system, mental retardation, low learning in psychoorganic syndrome, speech disorder, oligophrenia, impaired memory, cerebrosis, intellectual failure;
  • sickle cell anemia (as part of a comprehensive treatment).

Composition

1 solution contains:
active substance: Piracetam - 200.0 g
Excipients: sodium acetate, dilute acetic acid - to pH 5.0-5.8, water for injection

Piracetam is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Piracetam Pharmstandard Ufavita Russia solution
Piracetam-SOLOpharm Grotex Ltd Russia solution
Piracetam V-MIN LLC Russia pills
Piracetam Biochemist Russia solution
Piracetam PFK Obnovlenie Russia solution
Piracetam Ozon Russia pills
Piracetam Obolensky OP Russia pills
Lucetam Egis Hungary solution
Lucetam Egis Hungary pills
Nootropil UCB Pharma Belgium ampoules
Nootropil UCB Pharma Belgium pills
Nootropil UCB Pharma Belgium vials
Piracetam Synthesis AKOMP Russia capsules

No customer reviews for the moment.

Write your review

Write your review

Piracetam
  • Brand name: Piracetam
  • Active ingredient: Piracetam
  • Dosage form: Injection
  • Manufacturer: Pharmstandard Ufavita
  • Country of Origin: Russia

Studies and clinical trials of Piracetam (Click to expand)

  1. The influence of piracetam on actual driving behaviour of elderly subjects
  2. Determination of piracetam in rat plasma by LC–MS/MS and its application to pharmacokinetics
  3. Synthesis and Nootropic Activity of Some 2,3-Dihydro-1H-isoindol-1-one Derivatives Structurally Related with Piracetam
  4. The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam)
  5. Piracetam in the treatment of cognitive impairment in the elderly
  6. Electrophysiological profile of neurotropics (hydergine, piracetam, pyritinol) in organic brain disease in the aged
  7. Thermodynamic characterization of three polymorphic forms of piracetam
  8. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy
  9. Suppression of myoclonus in SCA2 by piracetam
  10. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease
  11. Effectiveness of piracetam in cortical myoclonus
  12. Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan
  13. Phenomenology of Polymorphism, III:p,TDiagram and Stability of Piracetam Polymorphs
  14. Age-related influence of piracetam on mitotic index and number of silver-stained nucleolus organizer regions
  15. The structure and conformations of piracetam (2-oxo-1-pyrrolidineacetamide): Gas-phase electron diffraction and quantum chemical calculations
  16. Rapid method for the sensitive determination of Piracetam in plasma by high-performance liquid chromatography
  17. Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection
  18. The investigation of the interaction between piracetam and bovine serum albumin by spectroscopic methods
  19. Determination of piracetam in serum by gas chromatography
  20. Determination of 2-oxo-pyrrolidine-1-acetamide (piracetam) in human plasma using high-performance liquid chromatography
  21. Determination of piracetam in human plasma by capillary electrophoresis
  22. Determination of piracetam and its impurities by TLC
  23. Determination of possible impurities in piracetam using FTIR spectroscopy
  24. GM1 and Piracetam Do Not Revert the Alcohol-Induced Depletion of Cholinergic Fibers in the Hippocampal Formation of the Rat

8 other products in the same category:

arrow_upward